董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert M. Davis Chairman, Chief Executive Officer and President 58 2318.61万美元 101.46 2025-04-09
Paul B. Rothman Director 67 41.38万美元 0.01 2025-04-09
Mary Ellen Coe Director 57 34.00万美元 0.0010 2025-04-09
Pamela J. Craig Director 68 40.38万美元 0.17 2025-04-09
Stephen L. Mayo Director 63 35.00万美元 0.01 2025-04-09
Christine E. Seidman Director 72 37.50万美元 0.01 2025-04-09
Douglas M. Baker, Jr. Director 66 35.00万美元 1.60 2025-04-09
Surendralal L. Karsanbhai Director 55 未披露 0.0001 2025-04-09
Risa J. Lavizzo Mourey Director 70 36.10万美元 0.10 2025-04-09
Thomas H. Glocer Director 65 43.63万美元 0.51 2025-04-09
Inge G. Thulin Director 71 34.00万美元 0.29 2025-04-09
Patricia F. Russo Director 72 36.38万美元 1.31 2025-04-09
Kathy J. Warden Director 53 35.00万美元 0.05 2025-04-09

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Robert M. Davis Chairman, Chief Executive Officer and President 58 2318.61万美元 101.46 2025-04-09
Sanat Chattopadhyay Executive Vice President and President, Merck Manufacturing Division 65 624.04万美元 未持股 2025-04-09
Chirfi Guindo Senior Vice President, Chief Marketing Officer, Human Health 59 1393.73万美元 未持股 2025-04-09
Betty D. Larson Executive Vice President and Chief Human Resources Officer 49 1125.78万美元 4.12 2025-04-09
Jennifer Zachary -- Executive Vice President and General Counsel 47 589.66万美元 未持股 2025-04-09
Dean Li Executive Vice President, President, Merck Research Laboratories 63 1008.63万美元 32.99 2025-04-09
Cristal Downing -- Executive Vice President and Chief Communications & Public Affairs Officer 56 未披露 未持股 2025-04-09
Caroline Litchfield Executive Vice President and Chief Financial Officer 56 750.78万美元 34.44 2025-04-09
David M. Williams Executive Vice President, Chief Information and Digital Officer 56 未披露 未持股 2025-04-09
Johannes J. Oosthuizen Senior Vice President and President Merck U.S. Human Health 57 未披露 未持股 2025-04-09
Joseph Romanelli Senior Vice President and President MSD International Human Health 51 未披露 未持股 2025-04-09
Dalton E. Smart III Senior Vice President Finance – Global Controller 59 未披露 未持股 2025-04-09
Richard R. Deluca, Jr. Executive Vice President and President, Merck Animal Health 62 909.85万美元 46.75 2025-04-09

董事简历

中英对照 |  中文 |  英文
Robert M. Davis

Robert M. Davis,自2014年4月起担任首席财务官,自2016年起担任全球服务首席财务官和执行副总裁,Merck,一家全球医疗保健公司,提供处方药物,疫苗和其他健康解决方案。在2021年2月,默克公司宣布他将成为默克公司的总裁,并于2021年4月1日生效,并于2021年7月1日生效,成为默克公司的首席执行官和董事会成员。默克公司之前,戴维斯先生曾为巴克斯特国际公司医疗产品的公司副总裁兼总裁从2010年到2014年巴克斯特国际公司的副总裁和总裁的业务在2010年从2006年到2010年公司副总裁和首席财务官,财务主管从2004年到2006年。Davis先生此前担任C.R. Bard的董事会成员,直到2017年12月与Becton, Dickinson and Company合并。


Robert M. Davis,Merck & Co., Inc.Chairman (2022-present);Chief Executive Officer and President (2021-present);Chief Financial Officer and Executive Vice President, Global Services (2016-2021);Chief Financial Officer and Executive Vice President (2014-2016);Baxter International, Inc.Corporate Vice President and President, Medical Products (2010-2014),Corporate Vice President and Chief Financial Officer (2006-2010),Corporate Vice President and Treasurer (2004-2006).
Robert M. Davis,自2014年4月起担任首席财务官,自2016年起担任全球服务首席财务官和执行副总裁,Merck,一家全球医疗保健公司,提供处方药物,疫苗和其他健康解决方案。在2021年2月,默克公司宣布他将成为默克公司的总裁,并于2021年4月1日生效,并于2021年7月1日生效,成为默克公司的首席执行官和董事会成员。默克公司之前,戴维斯先生曾为巴克斯特国际公司医疗产品的公司副总裁兼总裁从2010年到2014年巴克斯特国际公司的副总裁和总裁的业务在2010年从2006年到2010年公司副总裁和首席财务官,财务主管从2004年到2006年。Davis先生此前担任C.R. Bard的董事会成员,直到2017年12月与Becton, Dickinson and Company合并。
Robert M. Davis,Merck & Co., Inc.Chairman (2022-present);Chief Executive Officer and President (2021-present);Chief Financial Officer and Executive Vice President, Global Services (2016-2021);Chief Financial Officer and Executive Vice President (2014-2016);Baxter International, Inc.Corporate Vice President and President, Medical Products (2010-2014),Corporate Vice President and Chief Financial Officer (2006-2010),Corporate Vice President and Treasurer (2004-2006).
Paul B. Rothman

Paul B. Rothman,约翰霍普金斯大学医学院院长兼医学副院长(2012-2022);约翰霍普金斯医学院首席执行官(2012-2022);爱荷华大学卡弗医学院院长(2008-2012),内科主任(2004-2008)。


Paul B. Rothman,has served as a director of the Company and member of the Quality and Compliance Committee since June 2023. He has served as the Chair of the Quality and Compliance Committee since June 2024. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa. Dr. Rothman holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology and a Doctor of Medicine from Yale University.
Paul B. Rothman,约翰霍普金斯大学医学院院长兼医学副院长(2012-2022);约翰霍普金斯医学院首席执行官(2012-2022);爱荷华大学卡弗医学院院长(2008-2012),内科主任(2004-2008)。
Paul B. Rothman,has served as a director of the Company and member of the Quality and Compliance Committee since June 2023. He has served as the Chair of the Quality and Compliance Committee since June 2024. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa. Dr. Rothman holds a Bachelor of Science in Biology from the Massachusetts Institute of Technology and a Doctor of Medicine from Yale University.
Mary Ellen Coe

Mary Ellen Coe,她是公司的董事(2016年11月以来)。她曾一直担任Google的销售和产品运营副总裁(2012年11月以来)。


Mary Ellen Coe,YouTube Inc.,Chief Business Officer (2022-Present);Google Inc.,President, Google Customer Solutions (2017-2022),Vice President, Go-to-Market Vice President, Go-to-Market Operations and Strategy (2012-2017).
Mary Ellen Coe,她是公司的董事(2016年11月以来)。她曾一直担任Google的销售和产品运营副总裁(2012年11月以来)。
Mary Ellen Coe,YouTube Inc.,Chief Business Officer (2022-Present);Google Inc.,President, Google Customer Solutions (2017-2022),Vice President, Go-to-Market Vice President, Go-to-Market Operations and Strategy (2012-2017).
Pamela J. Craig

Pamela J. Craig是全球管理咨询、技术服务和外包公司埃森哲(AccenturePLC.)的退休首席财务官。在埃森哲任职34年期间,她在埃森哲担任过多个部门管理、咨询和运营方面的领导职务,此后于2006年至2013年担任埃森哲首席财务官。她在积极参与慈善组织、专注于教育和提高妇女在商业领域的地位方面有着长期的业绩记录,包括200人委员会、纽约妇女论坛、新泽西州青年成就组织和C200基金会。她担任全面发展公司董事会主席,该公司是一家非营利组织,为面临风险的纽约市高中生提供学术和社会服务支持。2013年9月,当选为阿卡迈技术有限公司董事。她曾在Accenture plc工作了34年,担任过运营和财务方面的多个职务,最后的是首席财务官,任期从2006年10起,直到2013年退休;该公司是全球性的管理顾问、技术服务及外包公司。2004年3月至2006年10月,她是Accenture的高级财务副总裁;2003年3月至2004年3月,担任其业务运营与服务部门总监;2001年6月至2003年3月,担任全球业务运营管理合伙人。2001年之前,她Accenture的不同业务部门担任过多个领导职务,涉及国内和国际的消费品、媒体及娱乐等行业。她还是Akamai Technologies的董事、审核委员会主席,以及Walmart Stores的董事、审核委员会成员。


Pamela J. Craig,is the former Chief Financial Officer of the global professional services firm, Accenture PLC. Ms. Craig worked at Accenture for 34 years in a variety of consulting and executive roles, where she developed extensive finance, capital management, operational, enterprise risk management, and technology expertise, as well as leadership experience in the context of a large, growth-oriented organization. In addition, her current and past service as a director of Progressive and other public companies, including companies in the retail, technology services and security, and manufacturing industries, and as a member of other audit, compensation, governance, and corporate responsibility and sustainability committees, provide her with valuable experience in addressing the many risks and governance issues facing public companies.
Pamela J. Craig是全球管理咨询、技术服务和外包公司埃森哲(AccenturePLC.)的退休首席财务官。在埃森哲任职34年期间,她在埃森哲担任过多个部门管理、咨询和运营方面的领导职务,此后于2006年至2013年担任埃森哲首席财务官。她在积极参与慈善组织、专注于教育和提高妇女在商业领域的地位方面有着长期的业绩记录,包括200人委员会、纽约妇女论坛、新泽西州青年成就组织和C200基金会。她担任全面发展公司董事会主席,该公司是一家非营利组织,为面临风险的纽约市高中生提供学术和社会服务支持。2013年9月,当选为阿卡迈技术有限公司董事。她曾在Accenture plc工作了34年,担任过运营和财务方面的多个职务,最后的是首席财务官,任期从2006年10起,直到2013年退休;该公司是全球性的管理顾问、技术服务及外包公司。2004年3月至2006年10月,她是Accenture的高级财务副总裁;2003年3月至2004年3月,担任其业务运营与服务部门总监;2001年6月至2003年3月,担任全球业务运营管理合伙人。2001年之前,她Accenture的不同业务部门担任过多个领导职务,涉及国内和国际的消费品、媒体及娱乐等行业。她还是Akamai Technologies的董事、审核委员会主席,以及Walmart Stores的董事、审核委员会成员。
Pamela J. Craig,is the former Chief Financial Officer of the global professional services firm, Accenture PLC. Ms. Craig worked at Accenture for 34 years in a variety of consulting and executive roles, where she developed extensive finance, capital management, operational, enterprise risk management, and technology expertise, as well as leadership experience in the context of a large, growth-oriented organization. In addition, her current and past service as a director of Progressive and other public companies, including companies in the retail, technology services and security, and manufacturing industries, and as a member of other audit, compensation, governance, and corporate responsibility and sustainability committees, provide her with valuable experience in addressing the many risks and governance issues facing public companies.
Stephen L. Mayo

Stephen L. Mayo,加州理工学院,生物与化学布伦教授2007-至今,生物与生物工程学部主任(2010-2020),副教务长(2007-2010)。霍华德·休斯医学研究所,非营利性医学研究组织,调查员(1994-2007年)。


Stephen L. Mayo,California Institute of Technology,Merkin Institute Professor (2021-present),Bren Professor of Biology and Chemistry (2007–present),Chair, Division of Biology and Biological Engineering (2010–2020),Vice Provost for Research (2007–2010);Howard Hughes Medical Institute,non-profit medical research organization,Investigator (1994–2007).
Stephen L. Mayo,加州理工学院,生物与化学布伦教授2007-至今,生物与生物工程学部主任(2010-2020),副教务长(2007-2010)。霍华德·休斯医学研究所,非营利性医学研究组织,调查员(1994-2007年)。
Stephen L. Mayo,California Institute of Technology,Merkin Institute Professor (2021-present),Bren Professor of Biology and Chemistry (2007–present),Chair, Division of Biology and Biological Engineering (2010–2020),Vice Provost for Research (2007–2010);Howard Hughes Medical Institute,non-profit medical research organization,Investigator (1994–2007).
Christine E. Seidman

Christine E. Seidman,哈佛大学医学院/布里格姆妇女医院,Thomas W. Smith医学和遗传学教授(2005-至今),遗传学和医学教授(1998-2005),医学教授(1997-1998)。霍华德·休斯医学研究所,非营利性医学研究组织,调查员(1994年至今)。布里格姆妇女医院,心血管遗传中心主任(1992年至今),心血管科主治医师(1987年至今)。


Christine E. Seidman,Harvard Medical School/Brigham and Women's Hospital (Harvard University),Thomas W. Smith Professor of Medicine and Genetics (2005-present),Professor of Genetics and Medicine (1998-2005),Professor of Medicine (1997-1998);Howard Hughes Medical Institute, non-profit medical research organization,Investigator (1994-present);Brigham and Women's Hospital,Director, Cardiovascular Genetics Center (1992-present),Attending Physician, Cardiovascular Division (1987-present).
Christine E. Seidman,哈佛大学医学院/布里格姆妇女医院,Thomas W. Smith医学和遗传学教授(2005-至今),遗传学和医学教授(1998-2005),医学教授(1997-1998)。霍华德·休斯医学研究所,非营利性医学研究组织,调查员(1994年至今)。布里格姆妇女医院,心血管遗传中心主任(1992年至今),心血管科主治医师(1987年至今)。
Christine E. Seidman,Harvard Medical School/Brigham and Women's Hospital (Harvard University),Thomas W. Smith Professor of Medicine and Genetics (2005-present),Professor of Genetics and Medicine (1998-2005),Professor of Medicine (1997-1998);Howard Hughes Medical Institute, non-profit medical research organization,Investigator (1994-present);Brigham and Women's Hospital,Director, Cardiovascular Genetics Center (1992-present),Attending Physician, Cardiovascular Division (1987-present).
Douglas M. Baker, Jr.

Douglas M. Baker, Jr.在公司治理、一般管理和组织管理方面拥有广泛的专业知识,包括对上市公司的全球营销、销售和运营有深刻的理解。Baker先生是E2SG Partners的创始合伙人,E2SG Partners投资于环境可持续技术。此前,Baker先生是Ecolab Inc.的董事长兼首席执行官,Ecolab Inc.是一家为食品、酒店、工业和能源市场提供水和卫生服务及技术的公司。Baker先生也是Target Corporation董事会成员,并于2015年至2021年担任其首席独立董事。这一董事职位以及他之前在U.S. Bancorp担任的董事职位,使他在大型上市公司面临的治理问题方面拥有丰富的经验。E2SG Partners,创始合伙人(2022至今)。Ecolab Inc.,执行主席(2021-2022年);董事长兼首席执行官(2006-2020年);首席执行官(2004-2006年)。


Douglas M. Baker, Jr.,is a Founding Partner of E2SG Partners, LP, a company that invests in new green technologies. He has served in this role since July 2022. Mr. Baker previously served as Executive Chairman of Ecolab Inc., a provider of water and hygiene services and technologies for the food, hospitality, industrial, and energy markets, from January 2021 through May 2022, and as Chairman of the Board & Chief Executive Officer from May 2006 to December 2020. He previously held various other leadership positions within Ecolab, including President and Chief Operating Officer.
Douglas M. Baker, Jr.在公司治理、一般管理和组织管理方面拥有广泛的专业知识,包括对上市公司的全球营销、销售和运营有深刻的理解。Baker先生是E2SG Partners的创始合伙人,E2SG Partners投资于环境可持续技术。此前,Baker先生是Ecolab Inc.的董事长兼首席执行官,Ecolab Inc.是一家为食品、酒店、工业和能源市场提供水和卫生服务及技术的公司。Baker先生也是Target Corporation董事会成员,并于2015年至2021年担任其首席独立董事。这一董事职位以及他之前在U.S. Bancorp担任的董事职位,使他在大型上市公司面临的治理问题方面拥有丰富的经验。E2SG Partners,创始合伙人(2022至今)。Ecolab Inc.,执行主席(2021-2022年);董事长兼首席执行官(2006-2020年);首席执行官(2004-2006年)。
Douglas M. Baker, Jr.,is a Founding Partner of E2SG Partners, LP, a company that invests in new green technologies. He has served in this role since July 2022. Mr. Baker previously served as Executive Chairman of Ecolab Inc., a provider of water and hygiene services and technologies for the food, hospitality, industrial, and energy markets, from January 2021 through May 2022, and as Chairman of the Board & Chief Executive Officer from May 2006 to December 2020. He previously held various other leadership positions within Ecolab, including President and Chief Operating Officer.
Surendralal L. Karsanbhai

Surendralal L. Karsanbhai,他于1995年加入Emerson,在2021年成为Emerson总裁兼首席执行官和董事会执行董事之前,他担任过各种职务,范围和责任不断增加。Karsanbhai先生还担任St. Louis Federal Reserve银行的副主席和美中贸易全国委员会的董事会成员。他持有Michigan大学的经济学学士学位和St. Louis Washington大学的工商管理硕士学位。


Surendralal L. Karsanbhai,joined Emerson in 1995 and held various roles increasing in scope and responsibility before becoming Emerson's president and chief executive officer and an executive director on its board in 2021. Mr. Karsanbhai also serves as deputy chair of the Federal Reserve Bank of St. Louis and on the board of the US-China Business Council. He holds a bachelor's degree in economics from the University of Michigan and a master's degree in business administration from Washington University in St. Louis.
Surendralal L. Karsanbhai,他于1995年加入Emerson,在2021年成为Emerson总裁兼首席执行官和董事会执行董事之前,他担任过各种职务,范围和责任不断增加。Karsanbhai先生还担任St. Louis Federal Reserve银行的副主席和美中贸易全国委员会的董事会成员。他持有Michigan大学的经济学学士学位和St. Louis Washington大学的工商管理硕士学位。
Surendralal L. Karsanbhai,joined Emerson in 1995 and held various roles increasing in scope and responsibility before becoming Emerson's president and chief executive officer and an executive director on its board in 2021. Mr. Karsanbhai also serves as deputy chair of the Federal Reserve Bank of St. Louis and on the board of the US-China Business Council. He holds a bachelor's degree in economics from the University of Michigan and a master's degree in business administration from Washington University in St. Louis.
Risa J. Lavizzo Mourey

Risa J. Lavizzo Mourey,宾夕法尼亚大学Robert Wood Johnson Foundation基金会人口健康与健康公平名誉教授(2021-至今),宾夕法尼亚大学健康公平与健康政策综合知识教授(2018-2021),Robert Wood Johnson Foundation会名誉主席(2017-至今),总裁兼首席执行官(2003-2017),高级副总裁兼董事(2001-2002)。


Risa J. Lavizzo Mourey,University of Pennsylvania,Robert Wood Johnson Foundation Population Health and Health Equity Professor Emerita (2021-Current),Penn Integrates Knowledge Professor of Health Equity and Health Policy(2018-2021);Robert Wood Johnson Foundation,President Emerita (2017-present),President and Chief Executive Officer (2003-2017),Senior Vice President and Director (2001-2002).
Risa J. Lavizzo Mourey,宾夕法尼亚大学Robert Wood Johnson Foundation基金会人口健康与健康公平名誉教授(2021-至今),宾夕法尼亚大学健康公平与健康政策综合知识教授(2018-2021),Robert Wood Johnson Foundation会名誉主席(2017-至今),总裁兼首席执行官(2003-2017),高级副总裁兼董事(2001-2002)。
Risa J. Lavizzo Mourey,University of Pennsylvania,Robert Wood Johnson Foundation Population Health and Health Equity Professor Emerita (2021-Current),Penn Integrates Knowledge Professor of Health Equity and Health Policy(2018-2021);Robert Wood Johnson Foundation,President Emerita (2017-present),President and Chief Executive Officer (2003-2017),Senior Vice President and Director (2001-2002).
Thomas H. Glocer

Thomas H. Glocer于2011年12月在Thomson Reuters Corporation辞去首席执行官的职务,在这之前,自2008年,他是Thomson Reuters的首席执行官,自2011年,他是Reuters Group PLC的首席执行官。Angelic Ventures, L.P的创始人和管理合伙人;美国对外关系委员会的董事;Morgan Stanley的提名董事;Trustees, Cleveland Clinic, European Business Leaders Council, Atlantic Council International Advisory Board, Madison Council of the Library of Congress, The Business Council, Advisory Board of the Cambridge Judge Business School, the Columbia College Board of Visitorshe 和president’s Council on International Activities at Yale University的董事会成员。2007年至2009年,Mr. Glocer也是Merck Sharp & Dohme Corp.(之前被称为Merck & Co., Inc)的董事;2000年至2008年,是Reuters Group PLC的董事;2008年至2011年,是Thomson Reuters Corporation的董事。


Thomas H. Glocer,Founder of Angelic Ventures, LP (Angelic), a family office focusing on early-stage investments in financial technology, cyber defense and media, and Managing Partner of Angelic since 2012;Served as CEO of Thomson Reuters, a news and information provider for businesses and professionals, from April 2008 through December 2011 and as CEO of Reuters Group PLC from July 2001 to April 2008. Joined Reuters Group PLC in 1993 and served in a variety of executive roles before being named CEO;Mergers and acquisitions lawyer at the law firm of Davis Polk & Wardwell LLP from 1984 to 1993.Educational:Columbia University, Bachelor's Degree;Yale Law School, Juris Doctor.
Thomas H. Glocer于2011年12月在Thomson Reuters Corporation辞去首席执行官的职务,在这之前,自2008年,他是Thomson Reuters的首席执行官,自2011年,他是Reuters Group PLC的首席执行官。Angelic Ventures, L.P的创始人和管理合伙人;美国对外关系委员会的董事;Morgan Stanley的提名董事;Trustees, Cleveland Clinic, European Business Leaders Council, Atlantic Council International Advisory Board, Madison Council of the Library of Congress, The Business Council, Advisory Board of the Cambridge Judge Business School, the Columbia College Board of Visitorshe 和president’s Council on International Activities at Yale University的董事会成员。2007年至2009年,Mr. Glocer也是Merck Sharp & Dohme Corp.(之前被称为Merck & Co., Inc)的董事;2000年至2008年,是Reuters Group PLC的董事;2008年至2011年,是Thomson Reuters Corporation的董事。
Thomas H. Glocer,Founder of Angelic Ventures, LP (Angelic), a family office focusing on early-stage investments in financial technology, cyber defense and media, and Managing Partner of Angelic since 2012;Served as CEO of Thomson Reuters, a news and information provider for businesses and professionals, from April 2008 through December 2011 and as CEO of Reuters Group PLC from July 2001 to April 2008. Joined Reuters Group PLC in 1993 and served in a variety of executive roles before being named CEO;Mergers and acquisitions lawyer at the law firm of Davis Polk & Wardwell LLP from 1984 to 1993.Educational:Columbia University, Bachelor's Degree;Yale Law School, Juris Doctor.
Inge G. Thulin

Inge G. Thulin,自2012年5月起担任3M公司董事长、总裁兼首席执行官。2012年2月24日至2012年5月8日,他担任3M公司总裁兼首席执行官。2011年5月至2012年2月,Thulin先生担任公司执行副总裁兼首席运营官,负责3M的所有业务部门和国际运营。在此之前,他从2004年到2011年担任国际运营执行副总裁。他也曾担任亚太、欧洲和中东以及多个业务的多个领导职位。Thulin在哥德堡大学获得经济学和市场营销学位。


Inge G. Thulin,3M Company, global technology company,Executive Chairman (2018-2019),Chairman, President and Chief Executive Officer (2012-2018),President and Chief Executive Officer (2012),Executive Vice President and Chief Operating Officer (2011-2012),Executive Vice President, International Operations (2004-2011).
Inge G. Thulin,自2012年5月起担任3M公司董事长、总裁兼首席执行官。2012年2月24日至2012年5月8日,他担任3M公司总裁兼首席执行官。2011年5月至2012年2月,Thulin先生担任公司执行副总裁兼首席运营官,负责3M的所有业务部门和国际运营。在此之前,他从2004年到2011年担任国际运营执行副总裁。他也曾担任亚太、欧洲和中东以及多个业务的多个领导职位。Thulin在哥德堡大学获得经济学和市场营销学位。
Inge G. Thulin,3M Company, global technology company,Executive Chairman (2018-2019),Chairman, President and Chief Executive Officer (2012-2018),President and Chief Executive Officer (2012),Executive Vice President and Chief Operating Officer (2011-2012),Executive Vice President, International Operations (2004-2011).
Patricia F. Russo

Patricia F. Russo,曾担任Kkr & Co. Inc.的成员。2011年4月起担任董事会成员。Russo女士从2006年到2008年担任Alcatel-Lucent的首席执行官。在2006年阿尔卡特和朗讯合并之前,她从2003年到2006年担任朗讯技术公司的董事长,从2002年到2006年担任总裁兼首席执行官。在2002年重新加入朗讯之前,她曾担任Eastman Kodak Company的总裁兼首席运营官(从2001年3月到2001年12月)。她曾担任Hewlett Packard Enterprise Company的董事长(2015年以来),默克公司(Merck & Co., Inc.)的董事(2009年以来),通用汽车公司(General Motors Company)的董事(2009年以来),包括首席独立董事(2010年3月至2014年1月)和首席独立董事(2021年6月以来)。在2009年与默克公司合并之前,Russo女士自1995年起担任Schering-Plough的董事,并于2011年至2015年11月担任Hewlett Packard Company的董事。从2016年11月到2018年5月,Russo女士还担任Arconic Inc.(从Alcoa Inc.分离出来)的董事会成员,从2008年到2016年11月,Russo女士担任董事。她毕业于乔治城大学,获得政治学和历史学学士学位,并获得哈佛商学院高级管理课程的高级管理学位。


Patricia F. Russo,has served as the Chair of the Hewlett-Packard Enterprise Company's ("HPE") board of directors since her appointment in 2015. She also served as Lead Director of HPE from 2014 to 2015. Ms. Russo was GM's Independent Lead Director from March 2010 to January 2014, and in 2021 she was re-appointed to that role. Ms. Russo served as CEO of Alcatel-Lucent S.A. from 2006 to 2008; Chairman and CEO of Lucent Technologies, Inc. from 2003 to 2006; and President and CEO of Lucent Technologies from 2002 to 2006.
Patricia F. Russo,曾担任Kkr & Co. Inc.的成员。2011年4月起担任董事会成员。Russo女士从2006年到2008年担任Alcatel-Lucent的首席执行官。在2006年阿尔卡特和朗讯合并之前,她从2003年到2006年担任朗讯技术公司的董事长,从2002年到2006年担任总裁兼首席执行官。在2002年重新加入朗讯之前,她曾担任Eastman Kodak Company的总裁兼首席运营官(从2001年3月到2001年12月)。她曾担任Hewlett Packard Enterprise Company的董事长(2015年以来),默克公司(Merck & Co., Inc.)的董事(2009年以来),通用汽车公司(General Motors Company)的董事(2009年以来),包括首席独立董事(2010年3月至2014年1月)和首席独立董事(2021年6月以来)。在2009年与默克公司合并之前,Russo女士自1995年起担任Schering-Plough的董事,并于2011年至2015年11月担任Hewlett Packard Company的董事。从2016年11月到2018年5月,Russo女士还担任Arconic Inc.(从Alcoa Inc.分离出来)的董事会成员,从2008年到2016年11月,Russo女士担任董事。她毕业于乔治城大学,获得政治学和历史学学士学位,并获得哈佛商学院高级管理课程的高级管理学位。
Patricia F. Russo,has served as the Chair of the Hewlett-Packard Enterprise Company's ("HPE") board of directors since her appointment in 2015. She also served as Lead Director of HPE from 2014 to 2015. Ms. Russo was GM's Independent Lead Director from March 2010 to January 2014, and in 2021 she was re-appointed to that role. Ms. Russo served as CEO of Alcatel-Lucent S.A. from 2006 to 2008; Chairman and CEO of Lucent Technologies, Inc. from 2003 to 2006; and President and CEO of Lucent Technologies from 2002 to 2006.
Kathy J. Warden

Kathy J. Warden,自2019年8月起担任Northrop Grumman Corporation董事长,自2019年1月起担任公司首席执行官和总裁。她自2018年7月起担任董事会成员。在成为首席执行官和总裁之前,Warden女士担任公司的总裁兼首席运营官从2018年1月到2018年12月公司的副总裁和总裁的任务系统部门从2016年到2017年公司副总裁和公司的前总裁信息系统部门从2013年到2015年,自2011年至2012年,担任公司网络情报部门的总裁。在2008年加入公司之前,她曾担任General Dynamics和Veridian Corporation的领导职务。此前,她曾担任一家风险互联网公司的负责人,并在通用电气公司(General Electric Company)的商业行业工作了近10年。她是Merck & Co.,Inc.的董事会成员。她还担任Aerospace Industries Association的主席,以及Catalyst的董事会成员。Warden女士也是James Madison University的董事会成员。她曾担任the Federal Reserve Bank of Richmond的董事会主席。从2011年至2012年担任智能网络部门副总裁兼总经理。2008-2011年,担任网络和信号业务副总裁。2007-2008年担任美国通用动力公司智能系统副总裁。


Kathy J. Warden,has served as Chair since August 2019 and as Chief Executive Officer and President of the Company since January 2019. She has served on the Board of Directors since July 2018. Prior to becoming CEO and President, Ms. Warden served as President and Chief Operating Officer of the Company from January 2018 through December 2018, as Corporate Vice President and President of the Company's Mission Systems Sector from 2016 through 2017, as Corporate Vice President and President of the Company's former Information Systems Sector from 2013 to 2015, and as Vice President of the Company's Cyber Intelligence Division from 2011 to 2012. Prior to joining the Company in 2008, Ms. Warden held leadership roles at General Dynamics and Veridian Corporation. Earlier, she was a principal in a venture internet firm and also spent nearly a decade with General Electric Company working in commercial industries.
Kathy J. Warden,自2019年8月起担任Northrop Grumman Corporation董事长,自2019年1月起担任公司首席执行官和总裁。她自2018年7月起担任董事会成员。在成为首席执行官和总裁之前,Warden女士担任公司的总裁兼首席运营官从2018年1月到2018年12月公司的副总裁和总裁的任务系统部门从2016年到2017年公司副总裁和公司的前总裁信息系统部门从2013年到2015年,自2011年至2012年,担任公司网络情报部门的总裁。在2008年加入公司之前,她曾担任General Dynamics和Veridian Corporation的领导职务。此前,她曾担任一家风险互联网公司的负责人,并在通用电气公司(General Electric Company)的商业行业工作了近10年。她是Merck & Co.,Inc.的董事会成员。她还担任Aerospace Industries Association的主席,以及Catalyst的董事会成员。Warden女士也是James Madison University的董事会成员。她曾担任the Federal Reserve Bank of Richmond的董事会主席。从2011年至2012年担任智能网络部门副总裁兼总经理。2008-2011年,担任网络和信号业务副总裁。2007-2008年担任美国通用动力公司智能系统副总裁。
Kathy J. Warden,has served as Chair since August 2019 and as Chief Executive Officer and President of the Company since January 2019. She has served on the Board of Directors since July 2018. Prior to becoming CEO and President, Ms. Warden served as President and Chief Operating Officer of the Company from January 2018 through December 2018, as Corporate Vice President and President of the Company's Mission Systems Sector from 2016 through 2017, as Corporate Vice President and President of the Company's former Information Systems Sector from 2013 to 2015, and as Vice President of the Company's Cyber Intelligence Division from 2011 to 2012. Prior to joining the Company in 2008, Ms. Warden held leadership roles at General Dynamics and Veridian Corporation. Earlier, she was a principal in a venture internet firm and also spent nearly a decade with General Electric Company working in commercial industries.

高管简历

中英对照 |  中文 |  英文
Robert M. Davis

Robert M. Davis,自2014年4月起担任首席财务官,自2016年起担任全球服务首席财务官和执行副总裁,Merck,一家全球医疗保健公司,提供处方药物,疫苗和其他健康解决方案。在2021年2月,默克公司宣布他将成为默克公司的总裁,并于2021年4月1日生效,并于2021年7月1日生效,成为默克公司的首席执行官和董事会成员。默克公司之前,戴维斯先生曾为巴克斯特国际公司医疗产品的公司副总裁兼总裁从2010年到2014年巴克斯特国际公司的副总裁和总裁的业务在2010年从2006年到2010年公司副总裁和首席财务官,财务主管从2004年到2006年。Davis先生此前担任C.R. Bard的董事会成员,直到2017年12月与Becton, Dickinson and Company合并。


Robert M. Davis,Merck & Co., Inc.Chairman (2022-present);Chief Executive Officer and President (2021-present);Chief Financial Officer and Executive Vice President, Global Services (2016-2021);Chief Financial Officer and Executive Vice President (2014-2016);Baxter International, Inc.Corporate Vice President and President, Medical Products (2010-2014),Corporate Vice President and Chief Financial Officer (2006-2010),Corporate Vice President and Treasurer (2004-2006).
Robert M. Davis,自2014年4月起担任首席财务官,自2016年起担任全球服务首席财务官和执行副总裁,Merck,一家全球医疗保健公司,提供处方药物,疫苗和其他健康解决方案。在2021年2月,默克公司宣布他将成为默克公司的总裁,并于2021年4月1日生效,并于2021年7月1日生效,成为默克公司的首席执行官和董事会成员。默克公司之前,戴维斯先生曾为巴克斯特国际公司医疗产品的公司副总裁兼总裁从2010年到2014年巴克斯特国际公司的副总裁和总裁的业务在2010年从2006年到2010年公司副总裁和首席财务官,财务主管从2004年到2006年。Davis先生此前担任C.R. Bard的董事会成员,直到2017年12月与Becton, Dickinson and Company合并。
Robert M. Davis,Merck & Co., Inc.Chairman (2022-present);Chief Executive Officer and President (2021-present);Chief Financial Officer and Executive Vice President, Global Services (2016-2021);Chief Financial Officer and Executive Vice President (2014-2016);Baxter International, Inc.Corporate Vice President and President, Medical Products (2010-2014),Corporate Vice President and Chief Financial Officer (2006-2010),Corporate Vice President and Treasurer (2004-2006).
Sanat Chattopadhyay

Sanat Chattopadhyay,目前担任Merck & Co.(纽约证券交易所代码:MRK)的董事,Merck & Co.(全球生物制药公司)的执行副总裁,以及制造部门的总裁,他自2016年以来一直担任此职位,此前曾担任运营高级副总裁(2009年至2016年)。加入Merck & Co.之前,他曾在Wyeth pharmaceuticals担任多个高级管理职位。Chattopadhyay先生持有the National Institute of Industrial Engineering的工业工程研究生学位和印度加尔各答Jadavpur University的化学工程学士学位。Chattopadhyay自2011年以来一直担任MSD Wellcome Trust Hilleman Laboratories的董事会成员,目前担任董事会主席(自2022年以来)。他也是薪酬和补偿委员会的成员。Chattopadhyay先生自2019年起担任美印战略伙伴关系论坛董事,自2016年起担任美印商会成员。


Sanat Chattopadhyay is the Executive Vice President and President, Manufacturing Division of Merck & Co. ("Merck") (NYSE: MRK), a global biopharmaceutical company, a position he has held since 2016. From 2009 to 2016, Mr. Chattopadhyay served as the Senior Vice President of Operations at Merck. Prior to joining Merck, Mr. Chattopadhyay served in vario senior executive roles at Wyeth Pharmaceuticals.Mr. Chattopadhyay holds a Bachelor of Science degree in Chemical Engineering from Jadavpur University, Kolkata, India and a post graduate degree in Indtrial Engineering from the Indian Institute of Management (IIM Mumbai), formerly known as the National Institute for Training in Indtrial Engineering (NITIE Mumbai).
Sanat Chattopadhyay,目前担任Merck & Co.(纽约证券交易所代码:MRK)的董事,Merck & Co.(全球生物制药公司)的执行副总裁,以及制造部门的总裁,他自2016年以来一直担任此职位,此前曾担任运营高级副总裁(2009年至2016年)。加入Merck & Co.之前,他曾在Wyeth pharmaceuticals担任多个高级管理职位。Chattopadhyay先生持有the National Institute of Industrial Engineering的工业工程研究生学位和印度加尔各答Jadavpur University的化学工程学士学位。Chattopadhyay自2011年以来一直担任MSD Wellcome Trust Hilleman Laboratories的董事会成员,目前担任董事会主席(自2022年以来)。他也是薪酬和补偿委员会的成员。Chattopadhyay先生自2019年起担任美印战略伙伴关系论坛董事,自2016年起担任美印商会成员。
Sanat Chattopadhyay is the Executive Vice President and President, Manufacturing Division of Merck & Co. ("Merck") (NYSE: MRK), a global biopharmaceutical company, a position he has held since 2016. From 2009 to 2016, Mr. Chattopadhyay served as the Senior Vice President of Operations at Merck. Prior to joining Merck, Mr. Chattopadhyay served in vario senior executive roles at Wyeth Pharmaceuticals.Mr. Chattopadhyay holds a Bachelor of Science degree in Chemical Engineering from Jadavpur University, Kolkata, India and a post graduate degree in Indtrial Engineering from the Indian Institute of Management (IIM Mumbai), formerly known as the National Institute for Training in Indtrial Engineering (NITIE Mumbai).
Chirfi Guindo

Chirfi Guindo自2019年2月起担任Biogen Inc.的执行副总裁,负责全球产品战略和商业化。此前,他曾担任Biogen Inc.的执行副总裁兼全球营销、市场准入和客户创新主管(2017年11月至2019年2月)。加入Biogen之前,他在全球制药行业工作了27年,并在Merck制药公司(加拿大、美国、法国、非洲和荷兰)担任多个领导职务。他曾在多个学科工作,包括财务、销售和市场营销、综合管理和全球战略/产品开发,涉及专业、急症和医院护理。2014年10月至2017年11月,他担任Merck Canada的副总裁兼董事总经理、总裁兼董事总经理。从2011年1月到2014年10月,他担任Merck公司全球艾滋病毒特许经营副总裁兼总经理。法国巴黎中央学校,工程专业;纽约大学斯特恩商学院,金融/经济学工商管理硕士。


Chirfi Guindo,Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022).
Chirfi Guindo自2019年2月起担任Biogen Inc.的执行副总裁,负责全球产品战略和商业化。此前,他曾担任Biogen Inc.的执行副总裁兼全球营销、市场准入和客户创新主管(2017年11月至2019年2月)。加入Biogen之前,他在全球制药行业工作了27年,并在Merck制药公司(加拿大、美国、法国、非洲和荷兰)担任多个领导职务。他曾在多个学科工作,包括财务、销售和市场营销、综合管理和全球战略/产品开发,涉及专业、急症和医院护理。2014年10月至2017年11月,他担任Merck Canada的副总裁兼董事总经理、总裁兼董事总经理。从2011年1月到2014年10月,他担任Merck公司全球艾滋病毒特许经营副总裁兼总经理。法国巴黎中央学校,工程专业;纽约大学斯特恩商学院,金融/经济学工商管理硕士。
Chirfi Guindo,Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022).
Betty D. Larson

Betty D. Larson自2018年7月以来担任Becton, Dickinson and Company人力资源执行副总裁兼首席人力资源官; 2017年12月至2018年7月,为介入事业部人力资源高级副总裁;自2018年7月以来担任人力资源执行副总裁兼首席人力资源官; 2017年12月至2018年7月,为介入事业部人力资源高级副总裁; 2014年9月至2017年12月为C.R. Bard,Inc.人力资源副总裁;在此之前,Larson是百特国际公司全球医疗产品业务人力资源副总裁。


Betty D. Larson,has served as the Chief People Officer of GE HealthCare since the Spin-Off. She served as the Chief People Officer of GE's healthcare business from February 2022 until the Spin-Off. Previously, she was EVP and Chief Human Resources Officer at Becton, Dickinson and Company ("BD"), a global medical technology company, responsible for HR, Communications and Social Investing from June 2018 to February 2022. Prior to that role, Ms. Larson served starting in September 2014 as Chief Human Resources Officer for C.R. Bard, Inc., a leading medical technology company in the fields of vascular, urology, and surgical specialty products, which was acquired by BD in 2017. She started her career at Baxter International, where she held a variety of leadership roles during her 16-year tenure. Ms. Larson currently serves on the Board of Directors of Fortrea Holdings Inc. (where she serves on the nominating, corporate governance and compliance committee and the management development and compensation committee) and Baxter Credit Union. She previously served on the Board of Directors of the Overlook Hospital Foundation, Summit Speech School, and the United Way of Lake County.
Betty D. Larson自2018年7月以来担任Becton, Dickinson and Company人力资源执行副总裁兼首席人力资源官; 2017年12月至2018年7月,为介入事业部人力资源高级副总裁;自2018年7月以来担任人力资源执行副总裁兼首席人力资源官; 2017年12月至2018年7月,为介入事业部人力资源高级副总裁; 2014年9月至2017年12月为C.R. Bard,Inc.人力资源副总裁;在此之前,Larson是百特国际公司全球医疗产品业务人力资源副总裁。
Betty D. Larson,has served as the Chief People Officer of GE HealthCare since the Spin-Off. She served as the Chief People Officer of GE's healthcare business from February 2022 until the Spin-Off. Previously, she was EVP and Chief Human Resources Officer at Becton, Dickinson and Company ("BD"), a global medical technology company, responsible for HR, Communications and Social Investing from June 2018 to February 2022. Prior to that role, Ms. Larson served starting in September 2014 as Chief Human Resources Officer for C.R. Bard, Inc., a leading medical technology company in the fields of vascular, urology, and surgical specialty products, which was acquired by BD in 2017. She started her career at Baxter International, where she held a variety of leadership roles during her 16-year tenure. Ms. Larson currently serves on the Board of Directors of Fortrea Holdings Inc. (where she serves on the nominating, corporate governance and compliance committee and the management development and compensation committee) and Baxter Credit Union. She previously served on the Board of Directors of the Overlook Hospital Foundation, Summit Speech School, and the United Way of Lake County.
Jennifer Zachary

Jennifer Zachary自2020年1月起担任执行副总裁,总法律顾问兼公司秘书; 执行副总裁兼总法律顾问(2018年4月至2020年1月); Covington&Burling LLP合伙人(2013年1月至2018年3月)。


Jennifer Zachary,Executive Vice President and General Counsel (since April 2018).
Jennifer Zachary自2020年1月起担任执行副总裁,总法律顾问兼公司秘书; 执行副总裁兼总法律顾问(2018年4月至2020年1月); Covington&Burling LLP合伙人(2013年1月至2018年3月)。
Jennifer Zachary,Executive Vice President and General Counsel (since April 2018).
Dean Li

Dean Li,执行副总裁、总裁,Merck研究实验室(自2021年1月起);Merck研究实验室发现科学与转化医学高级副总裁(2017年11月-2021年1月)。


Dean Li,Executive Vice President, President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021).
Dean Li,执行副总裁、总裁,Merck研究实验室(自2021年1月起);Merck研究实验室发现科学与转化医学高级副总裁(2017年11月-2021年1月)。
Dean Li,Executive Vice President, President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021).
Cristal Downing

Cristal Downing 执行副总裁兼首席传播与公共事务官,自 2021 年 8 月起; 医疗器械、全球传播和公共事务副总裁强生(2020 年 12 月至 2021 年 8 月); 强生公司财务传播副总裁(2018 年 1 月至 2020 年 12 月); 在此之前,强生公司高级传播总监。


Cristal Downing,Executive Vice President and Chief Communications & Public Affairs Officer (since August 2021); Prior to that, Vice President Medical Devices, Global Communications and Public Affairs Johnson & Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson & Johnson (January 2018-December 2020).
Cristal Downing 执行副总裁兼首席传播与公共事务官,自 2021 年 8 月起; 医疗器械、全球传播和公共事务副总裁强生(2020 年 12 月至 2021 年 8 月); 强生公司财务传播副总裁(2018 年 1 月至 2020 年 12 月); 在此之前,强生公司高级传播总监。
Cristal Downing,Executive Vice President and Chief Communications & Public Affairs Officer (since August 2021); Prior to that, Vice President Medical Devices, Global Communications and Public Affairs Johnson & Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson & Johnson (January 2018-December 2020).
Caroline Litchfield

Caroline Litchfield,执行副总裁兼首席财务官(自 2021 年 4 月起); 高级副总裁,企业财务主管(2018 年 1 月至 2021 年 3 月); 在此之前,全球人类健康高级副总裁。


Caroline Litchfield,currently serving as the Executive Vice President and Chief Financial Officer of Merck & Co., Inc., a global healthcare company, since 2021. In this role, she is responsible for overseeing the company's financial strategies and operations. Before becoming CFO, Caroline held several key positions within Merck. From 2019 to 2021, she served as the Senior Vice President and Treasurer, where she managed the company's treasury functions. Prior to that, from 2014 to 2018, she was the Senior Vice President of Finance for Global Human Health, contributing to the financial management of Merck's core business operations.
Caroline Litchfield,执行副总裁兼首席财务官(自 2021 年 4 月起); 高级副总裁,企业财务主管(2018 年 1 月至 2021 年 3 月); 在此之前,全球人类健康高级副总裁。
Caroline Litchfield,currently serving as the Executive Vice President and Chief Financial Officer of Merck & Co., Inc., a global healthcare company, since 2021. In this role, she is responsible for overseeing the company's financial strategies and operations. Before becoming CFO, Caroline held several key positions within Merck. From 2019 to 2021, she served as the Senior Vice President and Treasurer, where she managed the company's treasury functions. Prior to that, from 2014 to 2018, she was the Senior Vice President of Finance for Global Human Health, contributing to the financial management of Merck's core business operations.
David M. Williams

David M. Williams,执行副总裁、首席信息和数字官(自2020年8月起);代理首席信息和数字官(2019年12月- 2020年8月);Merck & Co., Inc.副总裁兼首席信息官(2017年5月至2019年12月)。


David M. Williams,Executive Vice President, Chief Information and Digital Officer (since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020); Vice President and Chief Information Officer, Merck Animal Health (May 2017-December 2019).
David M. Williams,执行副总裁、首席信息和数字官(自2020年8月起);代理首席信息和数字官(2019年12月- 2020年8月);Merck & Co., Inc.副总裁兼首席信息官(2017年5月至2019年12月)。
David M. Williams,Executive Vice President, Chief Information and Digital Officer (since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020); Vice President and Chief Information Officer, Merck Animal Health (May 2017-December 2019).
Johannes J. Oosthuizen

Johannes J. Oosthuizen,高级副总裁兼总裁-Merck U.S. Human Health(自2022年1月起);高级副总裁兼全球肿瘤商业主管(2021年1月至2021年12月);MSD K.K。高级副总裁兼总裁(2016年7月至2020年12月)。


Johannes J. Oosthuizen,Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020).
Johannes J. Oosthuizen,高级副总裁兼总裁-Merck U.S. Human Health(自2022年1月起);高级副总裁兼全球肿瘤商业主管(2021年1月至2021年12月);MSD K.K。高级副总裁兼总裁(2016年7月至2020年12月)。
Johannes J. Oosthuizen,Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020).
Joseph Romanelli

Joseph Romanelli,自2022年以来,他一直担任MSD(全球医疗保健公司,开发和制造药物、疫苗、生物疗法和动物保健产品)的Human Health International总裁。在这个职位上,他负责监督MSD在美国以外的75多个市场,领导着一个由14,000名同事组成的团队。在加入MSD之前,他曾担任JiXing Pharmaceuticals(一家中国生物制药公司)的首席执行官。此前,他在MSD和Schering-Plough担任过各种战略和运营职务,职责越来越重,时间长达25年。


Joseph Romanelli,President, Human Health International of Merck & Co., Inc., a biopharmaceutical company, since 2022;Chief Executive Officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company, from 2021 to 2022;Served in a number of leadership roles at Merck and Schering-Plough (which merged with Merck in 2009) from 1996 to 2021, including President MSD China from 2016 to 2021:Served approximately seven years in the Investor Relations area and led Merck's Investor Relations team as Vice President, Investor Relations from 2013 to 2015.
Joseph Romanelli,自2022年以来,他一直担任MSD(全球医疗保健公司,开发和制造药物、疫苗、生物疗法和动物保健产品)的Human Health International总裁。在这个职位上,他负责监督MSD在美国以外的75多个市场,领导着一个由14,000名同事组成的团队。在加入MSD之前,他曾担任JiXing Pharmaceuticals(一家中国生物制药公司)的首席执行官。此前,他在MSD和Schering-Plough担任过各种战略和运营职务,职责越来越重,时间长达25年。
Joseph Romanelli,President, Human Health International of Merck & Co., Inc., a biopharmaceutical company, since 2022;Chief Executive Officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company, from 2021 to 2022;Served in a number of leadership roles at Merck and Schering-Plough (which merged with Merck in 2009) from 1996 to 2021, including President MSD China from 2016 to 2021:Served approximately seven years in the Investor Relations area and led Merck's Investor Relations team as Vice President, Investor Relations from 2013 to 2015.
Dalton E. Smart III

Dalton E. Smart III,自2013年9月起担任Merck & Co., Inc.的助理财务总监。在被任命为Merck & Co., Inc.助理财务总监之前,Smart先生于2015年3月至2023年8月担任公司内部审计副总裁,并于2009年11月至2015年2月担任审计执行董事。


Dalton E. Smart III,Senior Vice President Finance – Global Controller (since December 2023); Vice President, Assistant Controller (September 2023-December 2023); Vice President, Internal Audit (March 2015-September 2023).
Dalton E. Smart III,自2013年9月起担任Merck & Co., Inc.的助理财务总监。在被任命为Merck & Co., Inc.助理财务总监之前,Smart先生于2015年3月至2023年8月担任公司内部审计副总裁,并于2009年11月至2015年2月担任审计执行董事。
Dalton E. Smart III,Senior Vice President Finance – Global Controller (since December 2023); Vice President, Assistant Controller (September 2023-December 2023); Vice President, Internal Audit (March 2015-September 2023).
Richard R. Deluca, Jr.

Richard R. Deluca, Jr.,2011年9月起担任Merck Animal Health, Merck & Co., Inc.执行副总裁和总裁;负责Merck Animal Health组织。


Richard R. Deluca, Jr.,Executive Vice President and President, Merck Animal Health (since September 2011).
Richard R. Deluca, Jr.,2011年9月起担任Merck Animal Health, Merck & Co., Inc.执行副总裁和总裁;负责Merck Animal Health组织。
Richard R. Deluca, Jr.,Executive Vice President and President, Merck Animal Health (since September 2011).